•
Mar 31, 2024

The Joint Q1 2024 Earnings Report

The Joint Corp. grew revenue and improved bottom-line year-over-year.

Key Takeaways

The Joint Corp. reported a 5% increase in revenue to $29.7 million and operating income of $1.1 million. Net income was $947,000, compared to $2.3 million in the previous year, which included a $3.9 million employee retention credit. System-wide sales increased by 9% to $126.3 million, and system-wide comp sales grew by 3%.

Revenue grew by 5% to $29.7 million.

Operating income was $1.1 million, compared to an operating loss of $653,000.

Net income was $947,000, compared to $2.3 million, which included a $3.9 million employee retention credit in the prior year.

System-wide sales increased by 9% to $126.3 million.

Total Revenue
$29.7M
Previous year: $28.5M
+4.5%
EPS
$0.06
Previous year: $0.15
-60.0%
Franchise Licenses Sold
15
Total Clinic Count
954
Gross Profit
$25.6M
Previous year: $25.8M
-0.9%
Cash and Equivalents
$18.7M
Previous year: $14.8M
+26.6%
Free Cash Flow
$2.42M
Previous year: $4.82M
-49.9%
Total Assets
$85.7M
Previous year: $99.6M
-14.0%

The Joint

The Joint

The Joint Revenue by Segment

Forward Guidance

The company reiterated all elements of its guidance.

Positive Outlook

  • 2024 System-wide sales are expected to be between $530 and $545 million dollars, compared to $488.0 million dollars in 2023.
  • System-wide comp sales for all clinics open 13 months or more are expected to be in the mid-single digits in 2024.
  • 2024 new franchised clinic openings, excluding the impact of refranchised clinics, are expected to be between 60 and 75, compared to 104 in 2023.

Revenue & Expenses

Visualization of income flow from segment revenue to net income